奥地利BIOCRATES Life Sciences AG
奥地利BIOCRATES生命科学公司是一家致力于代谢生物技术，产品应用于疾病检查，食品、药品检测的前沿技术开发公司。
该公司的研究和开发的重点在于两大支柱：一个是强大的生物标志物识别和面板，帮助识别疾病的危险，诊断疾病的验证，评估疾病的严重程度，指导治疗。 Biocrates制定了全面的生物标志物的管道，包括从慢性疾病，如Ⅱ型糖尿病，适应症，以急性事件，如中风。
另一种是支持发展生物标志物面板，帮助评估一个新的药物如何在人体内工作，并确定患者最有可能回应的待遇或至少可能遭受的副作用等研究机构。这种生物标志物，它正成为部分和-有针对性的治疗方法设计的一部分，被称为同伴诊断。
这种创新的，全面集成的代谢组学技术平台是基于质谱法，使一类生物分子有关的各种系统的量化在广泛的样本，从血液和血清细胞或组织。

Founded in 2002, Biocrates is dedicated to further developing and harnessing a relatively young technology referred to as metabolomics. The company’s research and development focus rests on two pillars:

One is the identification and validation of powerful biomarker panels that help identify disease risk, diagnose diseases, assess disease severity, and guide treatment. Biocrates has developed a comprehensive biomarker pipeline, covering indications from chronic disorders, such as type II diabetes, to acute events, such as stroke.
The other is to support other research organizations in developing biomarker panels that help assess how a new drug works in the body and identify patients most likely to respond to a treatment or least likely to suffer side effects. Such biomarkers, which are becoming part-and-parcel of the design of targeted therapies, are referred to as companion diagnostics.
This innovative, fully integrated technology platform for metabolomics is based on mass spectrometry, enabling the systematic quantification of a wide range of biologically relevant molecule classes in a wide range of samples, from blood and serum to cells or tissues.


BIOCRATES Life Sciences AG, a leading company in the field of diagnostic biomarker research.
Biomarkers are rapidly becoming the main drivers of innovation in the 21st century. Because they improve the potential to tailor treatment to the specific needs of individual patients, they are a critical prerequisite to personalized medicine.
Biocrates identifies and quantifies endogenous metabolites in body fluid or tissue samples and develops them into powerful biomarkers. By focusing on metabolites, we look at the functional endpoints of diseases and drug action—a technology called metabolomics.
Cutting-edge biomarker research stands to benefit everyone.

Research organizations will be able to enrich their diagnostics and drug development programs and save costs by better targeting their projects.
Physicians will be able to predict disease risk more reliably, establish diagnoses earlier, and tailor treatments more individually.
Patients will benefit from treatments that are more efficacious and have fewer side effects.
Investors can expect to be part of our cutting-edge science combined with sustained value creation.
Biocrates—bringing society one step closer to the goal of personalized medicine.